Identifying Prognostic Factors in Pleural Mesothelioma
Researchers have validated previously identified prognostic factors for pleural mesothelioma and identified “room for improvement” when predicting overall survival in this patient population.
Diagnosis & Disease Information
Cardiovascular Events After ICI Therapy “Common” in Lung Cancer
Cardiovascular toxicity related to immune checkpoint inhibitor therapy is “common” in patients with lung cancer, a new study suggests.
COVID-19 Vaccines Increase PD-L1 Levels, Might Reverse Treatment Resistance in NSCLC
New research suggests that mRNA COVID-19 vaccines can elevate PD-L1 expression levels in patients with advanced non-small cell lung cancer.
Adding Nivolumab to SABR Improves EFS in NSCLC
Adding nivolumab to treatment with SABR improved the 4-year event-free survival rate in a phase 2 trial of patients with NSCLC.
Can a Breath Test Detect Mesothelioma? It’s Too Soon to Tell.
Researchers are evaluating whether a breath test can detect malignant pleural mesothelioma in patients with asbestos exposure, and early results suggest it may be possible.
Tepotinib Plus Osimertinib May Provide Chemo-Free Option for NSCLC After First-Line Osimertinib
Tepotinib plus osimertinib has demonstrated efficacy in advanced, EGFR-mutant, MET-amplified NSCLC that progressed on first-line osimertinib.
Lung Cancer Patients Have High Burden of COVID-19 Death in Omicron Era
US patients with lung cancer have a higher burden of death from COVID-19 than the general population, and this has been the case since the omicron variant became dominant, data suggest.
Perioperative Durvalumab Does Not Impact Surgical Outcomes in NSCLC
Perioperative durvalumab does not adversely impact surgical outcomes in patients with resectable non-small cell lung cancer, results from the AEGEAN trial suggest.
Adding Serplulimab to Chemotherapy Improves Survival in Squamous NSCLC
First-line treatment with serplulimab plus chemotherapy improves survival over chemotherapy alone in patients with advanced squamous NSCLC, a phase 3 trial suggests.
First-Line Benmelstobart Regimen Produces Longest PFS, OS to Date in ES-SCLC
Adding benmelstobart and anlotinib to first-line chemotherapy improved survival outcomes in a phase 3 trial of patients with ES-SCLC.
- Loading...
Loading...
Next post in WCLC 2023
Loading... 
Loading...